Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development

References

• Alexandersen P, Karsdal MA, Qvist P, Reginster JY, Christiansen C. 2007. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone 40:218–222.
   PubMed Web of Science ®Google Scholar
• Andersson ML, Thorstensson CA, Roos EM, Petersson IF, Heinegard D, Saxne T. 2006. Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis. BMC. Musculoskelet Disord 7:98.
   PubMed Web of Science ®Google Scholar
• Avery NC, Bailey AJ. 2005a. Enzymic and non-enzymic cross-linking mechanisms in relation to turnover of collagen: relevance to aging and exercise. Scand J Med Sci Sports 15:231–240.
   PubMed Web of Science ®Google Scholar
• Bagger YZ, Tanko LB, Alexandersen P, Karsdal MA, Olson M, Mindeholm L, Azria M, Christiansen C. 2005. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: A new potential treatment of osteoarthritis. Bone 37:425–430.
   PubMed Web of Science ®Google Scholar
• Bailey AJ, Paul RG, Knott L. 1998. Mechanisms of maturation and ageing of collagen. Mech Ageing Dev 106:1–56.
   PubMed Web of Science ®Google Scholar
• Bailey AJ, Peach CM. 1968. Isolation and structural identification of a labile intermolecular crosslink in collagen. Biochem Biophys Res Commun 33:812–819.
   PubMed Web of Science ®Google Scholar
• Bank RA, Robins SP, Wijmenga C, Breslau-Siderius LG, Bardoel AF, van der Sluijs HA, Pruijs HE TeKoppele JM. 1999. Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: indications for a bone-specific telopeptide lysyl hydroxylase on chromosome 17. Proc Natl Acad Sci U S A 96:1054–1058.
   PubMed Web of Science ®Google Scholar
• Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, Heinegard D, Jordan JM, Kepler TB, Lane NE, Saxne T, Tyree B, Kraus VB. 2006. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 14:723–727.
   PubMed Web of Science ®Google Scholar
• Behrens F, Kraft EL Oegema TR Jr. 1989. Biochemical changes in articular cartilage after joint immobilization by casting or external fixation. J Orthop Res 7:335–343.
   PubMed Web of Science ®Google Scholar
• Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Bascil TN, Guvener DN. 2007. Rosiglitazone decreases serum bone- specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 92:3523–3530.
   PubMed Web of Science ®Google Scholar
• Bingham CO III, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Raynauld JP, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF. 2006. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54:3494–3507.
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. 2007. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822.
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR. 2006. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938.
   PubMed Web of Science ®Google Scholar
• Bleasel JF, Poole AR, Heinegard D, Saxne T, Holderbaum D, Ionescu M, Jones P, Moskowitz RW. 1999. Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation. Arthritis Rheum 42:39–45.
   PubMed Web of Science ®Google Scholar
• Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. 1995. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80:864–868.
   PubMed Web of Science ®Google Scholar
• Brady JD, Ju J, Robins SP. 1999. Isoaspartyl bond formation within N-terminal sequences of collagen type I: implications for their use as markers of collagen degradation. Clin Sci (Lond) 96:209–215.
   Google Scholar
• Buckland-Wright JC, Messent EA, Bingham CO III, Ward RJ, Tonkin C. 2007. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 46:257–264.
   PubMed Web of Science ®Google Scholar
• Byrjalsen I, Leeming DJ, Qvist P, Christiansen C, Karsdal MA. 2008. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int 19:339–348.
   PubMed Web of Science ®Google Scholar
• Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D. 2000. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:267–276.
   PubMed Web of Science ®Google Scholar
• Christgau S, Bitsch-Jensen O, Hanover BN, Gamwell HE, Qvist P, Alexandersen P, Bang HD. 2000. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26:505–511.
   PubMed Web of Science ®Google Scholar
• Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, Rosenquist C, Qvist P. 2001. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 29:209–215.
   PubMed Web of Science ®Google Scholar
• Christgau S, Rosenquist C, Alexandersen P, Bjarnason NH, Ravn P, Fledelius C, Herling C, Qvist P, Christiansen C. 1998. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 44:2290–2300.
   PubMed Web of Science ®Google Scholar
• Christgau S, Tanko LB, Cloos PA, Mouritzen U, Christiansen C, Delaisse JM, Hoegh-Andersen P. 2004. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 11:508–518.
   PubMed Web of Science ®Google Scholar
• Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C. 1988. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:1268–1274.
   PubMed Web of Science ®Google Scholar
• Cloos PA, Christgau S. 2004. Characterization of aged osteocalcin fragments derived from bone resorption. Clin Lab 50:585–598.
   Google Scholar
• Collins-Racie LA, Flannery CR, Zeng W, Corcoran C, Annis-Freeman B, Agostino MJ, Arai M, DiBlasio-Smith E, Dorner AJ, Georgiadis KE, Jin M, Tan XY, Morris EA, LaVallie ER. 2004. ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. Matrix Biol 23:219–230.
   PubMedGoogle Scholar
• Conrozier T, Poole AR, Ferrand F, Mathieu P, Vincent F, Piperno M, Verret C, Ionescu M, Vignon E. 2008. Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. Clin Exp Rheumatol 26:430–435.
   PubMed Web of Science ®Google Scholar
• Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, Wells G, Adachi J, Waldegger L, Guyatt G. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 23:540–551.
   PubMed Web of Science ®Google Scholar
• Crnkic M, Mansson B, Larsson L, Geborek P, Heinegard D, Saxne T. 2003. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 5:R181–R185.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM. 2002. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289.
   PubMed Web of Science ®Google Scholar
• Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C. 2008. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage (in press).
   Google Scholar
• Dam EB, Folkesson J, Pettersen PC, Christiansen C. 2007a. Automatic morphometric cartilage quantification in the medial tibial plateau from MRI for osteoarthritis grading. Osteoarthritis Cartilage 15:808–818.
   PubMed Web of Science ®Google Scholar
• Dam EB, Loog M, Christiansen C, Karsdal MA 2007b. Cartilage longevity: a prognostic OA biomarker combining biochemical and MRI-based cartilage markers. Osteoarthritis Cartilage 15(Suppl. C):C48.
   Google Scholar
• Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS, Woessner JF Jr. 1989. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 84:678–685.
   PubMed Web of Science ®Google Scholar
• Delmas PD. 1997. Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporos Int 7 (Suppl. 1):S3–S7.
   Google Scholar
• Duyk G. 2003. Attrition and translation. Science 302:603–605.
   PubMed Web of Science ®Google Scholar
• FDA. 2004. Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. Available at: http//:fda.gov/oc/initiatives/criticalpath/whitepaper.pdf. [last accessed 10 February 2009].
   Google Scholar
• Fledelius C, Johnsen AH, Cloos PA, Bonde M, Qvist P. 1997a. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J Biol Chem 272:9755–9763.
   PubMed Web of Science ®Google Scholar
• Folkesson J, Dam EB, Olsen OF, Karsdal MA, Pettersen P, Christiansen C. 2008. Automatic quantication of local and global articular cartilage surface curvature: biomarkers for osteoarthritis? Magnetic Resonance Med (in press).
   Google Scholar
• Folkesson J, Dam EB, Olsen OF, Pettersen PC, Christiansen C. 2007. Segmenting articular cartilage automatically using a voxel classification approach. IEEE Trans Med Imag 26:106–115.
   PubMed Web of Science ®Google Scholar
• Frank R, Hargreaves R. 2003. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2:566–580.
   PubMed Web of Science ®Google Scholar
• Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ. 2003. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum 48:3085–3095.
   PubMedGoogle Scholar
• Garnero P, Aronstein WS, Cohen SB, Conaghan PG, Cline GA, Christiansen C, Beary JF, Meyer JM, Bingham COIII. 2008. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 16:660–666.
   PubMed Web of Science ®Google Scholar
• Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, Delmas PD. 2002a. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46:2613–2624.
   PubMed Web of Science ®Google Scholar
• Garnero P, Cloos P, Sornay-Rendu E, Qvist P, Delmas PD. 2002b. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res 17:826–833.
   PubMed Web of Science ®Google Scholar
• Garnero P, Ferreras M, Karsdal MA, NicAmhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaisse JM. 2003. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859–867.
   PubMed Web of Science ®Google Scholar
• Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD. 1996. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531–1538.
   PubMed Web of Science ®Google Scholar
• Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang Z, Majumdar MK, Morris EA. 2005. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434:644–648.
   PubMed Web of Science ®Google Scholar
• Grados F, Brazier M, Kamel S, Mathieu M, Hurtebize N, Maamer M, Garabedian M, Sebert JL, Fardellone P. 2003. Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation. J Clin Endocrinol Metab 88:5175–5179.
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland - Ramsey L, Karpf DB. 1998. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431–1438.
   PubMed Web of Science ®Google Scholar
• Hellio Le Graverand MP, Brandt KD, Mazzuca SA, Katz BP, Buck R, Lane KA, Pickering E, Nemirovskiy OV, Sunyer T, Welsch DJ. 2006. Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. Osteoarthritis Cartilage 14:1189–1195.
   PubMed Web of Science ®Google Scholar
• Helminen HJ, Saamanen AM, Salminen H, Hyttinen MM. 2002. Transgenic mouse models for studying the role of cartilage macromolecules in osteoarthritis. Rheumatology (Oxford) 41:848–856.
   Google Scholar
• Henriksen K, Gram J, Hoegh-Andersen P, Jemtland R, Ueland T, Dziegiel MH, Schaller S, Bollerslev J, Karsdal MA. 2005. Osteoclasts from patients with Autosomal Dominant Osteopetrosis type I (ADOI) caused by a T253I mutation in LRP5 are normal in vitro, but have decreased resorption capacity in vivo. Am J Pathol 167:1341–1348.
   PubMed Web of Science ®Google Scholar
• Henriksen K, Gram J, Schaller S, Dahl BH, Dziegiel MH, Bollerslev J, Karsdal MA. 2004. Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J Pathol 164:1537–1545.
   PubMed Web of Science ®Google Scholar
• Henriksen K, Leeming DJ, Byrjalsen I, Nielsen RH, Sorensen MG, Dziegiel MH, Martin TJ, Christiansen C, Qvist P, Karsdal MA. 2007a. Osteoclasts prefer aged bone. Osteoporos Int 18:751–759.
   PubMed Web of Science ®Google Scholar
• Henriksen K, Sorensen MG, Nielsen RH, Gram J, Schaller S, Dziegiel MH, Everts V, Bollerslev J, Karsdal MA. 2006. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification. J Bone Miner Res 21:58–66.
   PubMed Web of Science ®Google Scholar
• Henriksen K, Tanko LB, Qvist P, Delmas PD, Christiansen C, Karsdal MA. 2007b. Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 18:681–685.
   PubMed Web of Science ®Google Scholar
• Hilton JM, Dowton M, Houssami S, Sexton PM. 2000. Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors. J Endocrinol 166:213–226.
   Google Scholar
• Hoegh-Andersen P, Tanko LB, Andersen TL, Lundberg CV, Mo JA, Heegaard AM, Delaisse JM, Christgau S. 2004. Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. Arthritis Res Ther 6:R169–R180.
   PubMed Web of Science ®Google Scholar
• Horrobin DF. 2003. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nat Rev Drug Discov 2:151–154.
   PubMed Web of Science ®Google Scholar
• Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ. 1998. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 338:485–492.
   PubMed Web of Science ®Google Scholar
• Hou WS, Bromme D, Zhao Y, Mehler E, Dushey C, Weinstein H, Miranda CS, Fraga C, Greig F, Carey J, Rimoin DL, Desnick RJ, Gelb BD. 1999. Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J Clin Invest 103:731–738.
   PubMed Web of Science ®Google Scholar
• Hui W, Rowan AD, Richards CD, Cawston TE. 2003. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum 48:3404–3418.
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ III, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A. 2005. Predictive Value of BMD for Hip and Other Fractures. J Bone Miner Res 20:1185–1194.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Leeming DJ, Delmas PD, Christiansen C. 2008a. The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos. Int. 19:1355–1361.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Byrjalsen I, Leeming DJ, Qvist P, Christiansen C. 2007a. Bone turnover and quality: how discrepancies in BMD changes and fracture risk may be explained. J Bone Miner Res 22(Suppl. 1): W478.
   Google Scholar
• Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. 2008b. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of salmon calcitonin. BMC Clin Pharmacol 8:5.
   PubMedGoogle Scholar
• Karsdal MA, Henriksen K, Sorensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C, Bollerslev J. 2005. Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467–476.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Hjorth P, Henriksen K, Kirkegaard T, Nielsen KL, Lou H, Delaisse JM, Foged NT. 2003. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 278:44975–44987.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P, Altman RD, Christiansen C. 2008c. Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 16:638–646.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard BC. 2008d. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 10:R63.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K. 2007b. Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22:487–494.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Neutzsky-Wulff AV, Dziegiel MH, Christiansen C, Henriksen K. 2008e. Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun 366:483–488.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Qvist P, Christiansen C, Tanko LB. 2006. Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression? Drugs. 66:1909–1918.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Sumer EU, Wulf H, Madsen SH, Christiansen C, Fosang AJ, Sondergaard BC. 2007c. Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase- mediated cartilage degradation, but not aggrecanase- mediated cartilage degradation. Arthritis Rheum 56:1549–1558.
   PubMed Web of Science ®Google Scholar
• Kellgren JH, Lawrence JS. 1957. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16:494–501.
   PubMed Web of Science ®Google Scholar
• Kerin A, Patwari P, Kuettner K, Cole A, Grodzinsky A. 2002. Molecular basis of osteoarthritis: biomechanical aspects. Cell Mol Life Sci 59:27–35.
   PubMed Web of Science ®Google Scholar
• Kiani C, Chen L, Wu YJ, Yee AJ, Yang BB. 2002. Structure and function of aggrecan. Cell Res 12:19–32.
   PubMed Web of Science ®Google Scholar
• Kim SW, Park DJ, Park kS, Kim SY, Cho BY, Lee HK, Shin CS. 2005. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 52:667–674.
   PubMed Web of Science ®Google Scholar
• Kondo S, Cha SH, Xie WF, Sandell LJ. 2001. Cytokine regulation of cartilage-derived retinoic acid-sensitive protein (CD-RAP) in primary articular chondrocytes: suppression by IL-1, bfGF, TGFbeta and stimulation by IGF-1. J Orthop Res 19:712–719.
   PubMed Web of Science ®Google Scholar
• Koshy PJ, Lundy CJ, Rowan AD, Porter S, Edwards DR, Hogan A, Clark IM, Cawston TE. 2002. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 46:961–967.
   PubMed Web of Science ®Google Scholar
• Krzeski P, Buckland-Wright C, Balint G, Cline GA, Stoner K, Lyon R, Beary J, Aronstein WS, Spector TD. 2007. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 9:R109.
   PubMed Web of Science ®Google Scholar
• Lathia CD. 2002. Biomarkers and surrogate endpoints: how and when might they impact drug development? Dis Markers 18:83–90.
   PubMedGoogle Scholar
• Leeming DJ, Alexandersen P, Karsdal MA, Qvist P, Schaller S, Tanko LB. 2006a. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 62:781–792.
   PubMed Web of Science ®Google Scholar
• Leeming DJ, Delling G, Koizumi M, Henriksen K, Karsdal MA, Li B, Qvist P, Tanko LB, Byrjalsen I. 2006b. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion. Cancer Epidemiol. Biomarkers Prev. 15:1392–1395.
   PubMed Web of Science ®Google Scholar
• Leeming DJ, Koizumi M., Byrjalsen I., Li B, Qvist P, Tanko LB. 2006c. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15:32–38.
   PubMed Web of Science ®Google Scholar
• Lesko LJ, Atkinson AJ Jr. 2001. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41:347–366.
   PubMed Web of Science ®Google Scholar
• Little CB, Meeker CT, Hembry RM, Sims NA, Lawlor KE, Golub SB, Last K, Fosang AJ. 2005a. Matrix metalloproteinases are not essential for aggrecan turnover during normal skeletal growth and development. Mol Cell Biol 25:3388–3399.
   PubMed Web of Science ®Google Scholar
• Little CB, Mittaz L, Belluoccio D, Rogerson FM, Campbell IK, Meeker CT, Bateman JF, Pritchard MA, Fosang AJ. 2005b. ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. Arthritis Rheum 52:1461–1472.
   PubMed Web of Science ®Google Scholar
• Lohmander LS, Saxne T, Heinegard DK. 1994. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis 53:8–13.
   PubMed Web of Science ®Google Scholar
• Lozada CJ, Altman RD. 1999. Animal models of cartilage breakdown. In: Dynamics of Bone and Cartilage Disorders. Seibel MJ, Bilezikian JP, Robins SP, editors. Elsevier Science & Technology Books; p. 339–352.
   Google Scholar
• Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP. 2006. Oral salmon calcitonin reduces Lequesne’s algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 54:3205–3211.
   PubMed Web of Science ®Google Scholar
• Mansell JP, Collins C, Bailey AJ. 2007. Bone, not cartilage, should be the major focus in osteoarthritis. Nat Clin Pract Rheumatol 3:306–307.
   PubMedGoogle Scholar
• Martel-Pelletier J, Alaaeddine N, Pelletier JP. 1999. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 4:D694–D703.
   PubMedGoogle Scholar
• McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ. 2006. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831.
   PubMed Web of Science ®Google Scholar
• Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. 2008. Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820–825.
   PubMed Web of Science ®Google Scholar
• Melton LJIII, Atkinson EJ, O’Fallon WM, Wahner HW, Riggs BL. 1993. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8:1227–1233.
   PubMed Web of Science ®Google Scholar
• Mercer DK, Nicol PF, Kimbembe C, Robins SP. 2003. Identification, expression, and tissue distribution of the three rat lysyl hydroxylase isoforms. Biochem Biophys Res Commun 307:803–809.
   PubMed Web of Science ®Google Scholar
• Meymeh RH, Wooltorton E. 2007. Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ 177:723–724.
   PubMed Web of Science ®Google Scholar
• Mort JS, Flannery CR, Makkerh J, Krupa JC, Lee ER. 2003. Use of anti-neoepitope antibodies for the analysis of degradative events in cartilage and the molecular basis for neoepitope specificity. Biochem Soc Symp107–114.
   Google Scholar
• Mouritzen U, Christgau S, Lehmann HJ, Tanko LB, Christiansen C. 2003. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 62:332–336.
   PubMed Web of Science ®Google Scholar
• Mullan RH, Matthews C, Bresnihan B, FitzGerald O, King L, Poole AR, Fearon U, and Veale DJ. 2007. Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. Arthritis Rheum. 56:2919–2928.
   PubMed Web of Science ®Google Scholar
• Murphy G, Nagase H. 2008. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol 4:128–135.
   PubMedGoogle Scholar
• Nemirovskiy OV, Dufield DR, Sunyer T, Aggarwal P, Welsch DJ, Mathews WR. 2007. Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. Anal Biochem 361:93–101.
   PubMed Web of Science ®Google Scholar
• Nemirovskiy OV, Sunyer T, Aggarwal P, Abrams M, Hellio Le Graverand MP, Mathews WR. 2008. Discovery and development of the N-terminal procollagen type II (NPII) biomarker: a tool for measuring collagen type II synthesis. Osteoarthritis Cartilage 16:1494–1500.
   Google Scholar
• Nielsen RH, Stoop R, Leeming DJ, Stolina M, Qvist P, Christiansen P, Karsdal MA. 2007. Evaluation of cartilage damage by measuring collagen degradation products in joint extracts in a traumatic model of osteoarthritis. Biomarkers 1–9.
   Google Scholar
• Nishi Y, Atley L, Eyre DE, Edelson JG, Superti-Furga A, Yasuda T, Desnick RJ, Gelb Bd. 1999. Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res 14:1902–1908.
   PubMed Web of Science ®Google Scholar
• Oestergaard S, Chouinard L, Doyle N, Karsdal MA, Smith SY, Qvist P, Tanko LB. 2006a. The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. Osteoarthritis Cartilage 14:670–679.
   PubMed Web of Science ®Google Scholar
• Oestergaard S, Chouinard L, Doyle N, Smith SY, Tanko LB, Qvist P. 2006b. Early elevation in circulating levels of C-telopeptides of type II collagen predicts structural damage in articular cartilage in the rodent model of collagen-induced arthritis. Arthritis Rheum 54:2886–2890.
   Google Scholar
• Oestergaard S, Sondergaard BC, Hoegh-Andersen P, Henriksen K, Qvist P, Christiansen C, Tanko LB, Karsdal MA. 2006c. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 54:2441–2451.
   PubMed Web of Science ®Google Scholar
• Okabe R, Inaba M, Nakatsuka K, Miki T, Naka H, Moriguchi A, Nishizawa Y. 2004. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy, comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab 22:127–131.
   PubMed Web of Science ®Google Scholar
• Olsen AK, Sondergaard BC, Byrjalsen I, Tanko LB, Christiansen C, Muller A, Hein GE, Karsdal MA, Qvist P. 2007. Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 15:335–342.
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Stein CM. 2004. New drugs for rheumatoid arthritis. N Engl J Med 350:2167–2179.
   PubMed Web of Science ®Google Scholar
• Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS. 1989. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) 30:435–442.
   PubMed Web of Science ®Google Scholar
• Oxlund H, Barckman M, Ortoft G, Andreassen TT. 1995. Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone 17:365S–371S.
   PubMed Web of Science ®Google Scholar
• Pelletier JP, Boileau C, Brunet J, Boily M, Lajeunesse D, Reboul P, Laufer S, Martel-Pelletier J. 2004. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone 34:527–538.
   Google Scholar
• Poole AR, Dieppe P. 1994. Biological markers in rheumatoid arthritis. Semin Arthritis Rheum 23:17–31.
   PubMed Web of Science ®Google Scholar
• Purdue BW, Tilakaratne N, Sexton PM. 2002. Molecular pharmacology of the calcitonin receptor. Receptors Channels 8:243–255.
   PubMedGoogle Scholar
• Qazi AA, Folkesson J, Pettersen PC, Karsdal MA, Christiansen C, Dam EB. 2007. Separation of healthy and early osteoarthritis by automatic quantification of cartilage homogeneity. Osteoarthritis Cartilage 15:1199–1206.
   PubMed Web of Science ®Google Scholar
• Qvist P, Bay-Jensen AC, Christiansen C, Dam EB, Pastoureau P, Karsdal MA. 2008. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacol Res 58:1–7.
   PubMed Web of Science ®Google Scholar
• Radabaugh MR, Nemirovskiy OV, Misko TP, Aggarwal P, Mathews WR. 2008. Immunoaffinity liquid chromatography-tandem mass spectrometry detection of nitrotyrosine in biological fluids: development of a clinically translatable biomarker. Anal Biochem 380:68–76.
   PubMed Web of Science ®Google Scholar
• Ravn P, Clemmesen B, Christiansen C. 1999a. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237–244.
   PubMed Web of Science ®Google Scholar
• Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C. 1999b. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363–2368.
   PubMed Web of Science ®Google Scholar
• Ravn P, Thompson D, Ross PD, Christiansen C. 2003. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33:150–158.
   PubMed Web of Science ®Google Scholar
• Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ, Daifotis A, Fuleihan GE. 2000. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 85:1492–1497.
   PubMed Web of Science ®Google Scholar
• Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-Pelletier J. 1996. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. J Clin Invest 97:2011–2019.
   PubMed Web of Science ®Google Scholar
• Recker R, Lappe J, Davies KM, Heaney R. 2004. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 19:1628–1633.
   PubMed Web of Science ®Google Scholar
• Reginster JY, Henrotin Y, Christiansen C, Gamwell-Henriksen E, Bruyere, Collette J, Christgau S. 2001b. Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif Tissue Int 69:130–137.
   PubMed Web of Science ®Google Scholar
• Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, Uitterlinden AG, Pols HA. 2004. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 50:2471–2478.
   PubMed Web of Science ®Google Scholar
• Rodan GA, Martin TJ. 2000. Therapeutic approaches to bone diseases. Science 289:1508–1514.
   PubMed Web of Science ®Google Scholar
• Roodman GD. 1999. Cell biology of the osteoclast. Exp Hematol 27:1229–1241.
   PubMed Web of Science ®Google Scholar
• Rosen CJ, Chesnut CH III, Mallinak NJ. 1997. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82:1904–1910.
   PubMed Web of Science ®Google Scholar
• Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C. 1998. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44:2281–2289.
   PubMed Web of Science ®Google Scholar
• Rousseau JC, Delmas PD. 2007. Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 3:346–356.
   PubMedGoogle Scholar
• Rousseau JC, Sandell LJ, Delmas PD, Garnero P. 2004a. Development and clinical application in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide. Methods Mol Med 101:25–37.
   PubMedGoogle Scholar
• Rousseau JC, Zhu Y, Miossec P, Vignon E, Sandell LJ, Garnero P, Delmas PD. 2004b. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 12:440–447.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. 2004. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394–401.
   PubMed Web of Science ®Google Scholar
• Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, Risteli J. 2000. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26:367–373.
   PubMed Web of Science ®Google Scholar
• Saxne T, Heinegard D. 1992. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 31:583–591.
   PubMedGoogle Scholar
• Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, Tanko LB, Qvist P, Karsdal MA. 2005a. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 3:553–580.
   PubMed Web of Science ®Google Scholar
• Schaller S, Henriksen K, Sorensen MG, and Karsdal MA. 2005b. The role of chloride channels in osteoclasts: ClC-7 as a target for osteoporosis treatment. Drug News Perspect 18:489–495.
   PubMedGoogle Scholar
• Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Helix N, Stahlhut M, Ovejero MC, Johansen JV, Solberg H, Andersen TL, Hougaard D, Berryman M, Shiodt CB, Sorensen BH, LichtenbergJ, Christophersen P, Foged NT, Delaisse JM, Engsig MT, Karsdal MA. 2004. The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 19:1144–1153.
   PubMed Web of Science ®Google Scholar
• Seeman E, Delmas PD. 2006. Bone quality – the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–2261.
   PubMed Web of Science ®Google Scholar
• Sell DR, Monnier VM. 1989. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 264:21597–21602.
   PubMed Web of Science ®Google Scholar
• Sexton PM, Findlay DM, Martin TJ. 1999. Calcitonin. Curr Med Chem 6:1067–1093.
   PubMed Web of Science ®Google Scholar
• Short R. 2007. Fracture risk is a class effect of glitazones. BMJ 334:551.
   PubMed Web of Science ®Google Scholar
• Sondergaard BC, Henriksen K, Wulf H, Oestergaard S, Schurigt U, Brauer R, Danielsen I, Christiansen C, Qvist P, Karsdal MA. 2006a. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 14:738–748.
   PubMed Web of Science ®Google Scholar
• Sondergaard BC, Wulf H, Henriksen K, Schaller S, Oestergaard S, Qvist P, Tanko LB, Bagger YZ, Christiansen C, Karsdal MA. 2006b. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage 14:759–768.
   PubMed Web of Science ®Google Scholar
• Sorensen MG, Henriksen K, Neutzsky-Wulff AV, Dziegiel MH, Karsdal MA. 2007a. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J Bone Miner Res 22:1640–1648.
   PubMed Web of Science ®Google Scholar
• Sorensen MG, Henriksen K, Schaller S, Henriksen DB, Nielsen FC, Dziegiel MH, Karsdal MA. 2007b. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J Bone Miner Metab 25:36–45.
   PubMed Web of Science ®Google Scholar
• Sorensen MG, Henriksen K, Schaller S, Karsdal MA. 2007c. Biochemical markers in pre-clinical models of osteoporosis. Biomarkers (in press).
   Google Scholar
• Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, Valent DJ, Meyer JM. 2005b. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 7:R625–R633.
   PubMed Web of Science ®Google Scholar
• Srivastava AK, Bhattacharyya S, Castillo G, Wergedal J, Mohan S, Baylink DJ. 2000. Development and application of a serum C-telopeptide and osteocalcin assay to measure bone turnover in an ovariectomized rat model. Calcif Tissue Int 66:435–442.
   PubMed Web of Science ®Google Scholar
• Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, Little CB, Last K, Farmer PJ, Campbell IK, Fourie AM, Fosang AJ. 2005a. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434:648–652.
   PubMed Web of Science ®Google Scholar
• Stoop R, van der Kraan PM, Buma P, Hollander AP, Poole AR, Van den Berg WB. 1999. Denaturation of type II collagen in articular cartilage in experimental murine arthritis. Evidence for collagen degradation in both reversible and irreversible cartilage damage. J Pathol 188:329–337.
   PubMed Web of Science ®Google Scholar
• Sumer EU, Schaller S, Sondergaard BC, Tanko LB, Qvist P. 2006. Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review. Biomarkers 11:485–506.
   PubMed Web of Science ®Google Scholar
• Sumer EU, Sondergaard BC, Rousseau JC, Delmas PD, Fosang AJ, Karsdal MA, Christiansen C, Qvist P. 2007. MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. Osteoarthritis Cartilage 15:212–221.
   PubMed Web of Science ®Google Scholar
• Tang BL. 2001. ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol 33:33–44.
   PubMed Web of Science ®Google Scholar
• Tanko LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C. 2004. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 19:1531–1538.
   PubMed Web of Science ®Google Scholar
• Van den Berg WB. 2002. Lessons from animal models of arthritis. Curr Rheumatol Rep 4:232–239.
   Google Scholar
• van Meurs JB, van Lent PL, Holthuysen AE, Singer II, Bayne EK, Van den Berg WB. 1999. Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum 42:1128–1139.
   PubMedGoogle Scholar
• Wagner JA. 2002. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 18:41–46.
   PubMed Web of Science ®Google Scholar